From EADV: Bimekizumab Shows Sustained Efficacy in Plaque Psoriasis and HS
Key Takeaways
Three-year hidradenitis suppurativa (HS)data showed sustained HiSCR and IHS4 responses, particularly in patients treated earlier.
In plaque psoriasis, 48.9% of PASI 0 responders maintained clearance through year four.
No new safety concerns were observed in either disease population over long-term follow-up.
New data presented by UCB at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris both showed sustained efficacy and tolerability for BIMZELX® (bimekizumab-bkzx) in both moderate-to-severe hidradenitis suppurativa (HS) and plaque psoriasis.
Hidradenitis Suppurativa
Study researchers presented 3-year follow-up data from the BE HEARD trials, showing continued clinical response among adults with moderate-to-severe HS receiving bimekizumab. “The three-year data on bimekizumab presented at EADV demonstrated deep and sustained responses across stringent efficacy endpoints, as well as long-term improvements in health-related quality of life for people living with hidradenitis suppurativa,” said in a press release from UCB.
Patients demonstrated durable skin lesion clearance, with HiSCR75, HiSCR90, and HiSCR100 responses maintained in 81.2%, 64.3%, and 50.1% of patients, respectively, at 3 years. Among those who achieved complete resolution of inflammatory lesions (IHS4-100) at year one, 64.3% sustained that response into year 2. Early initiation of bimekizumab treatment was linked with improve outcomes, particularly in high-efficacy IHS4 thresholds. The safety profile remained consistent through 3 years.
"A crucial goal for treating people with hidradenitis suppurativa is achieving and maintaining long-term disease control at the most stringent levels," said Prof. John Ingram, Professor of Dermatology, Cardiff University, in a press release from the manufacturer. "These data for bimekizumab – including HiSCR100 and IHS4-100 – showed symptom relief can be maintained long-term."
Plaque Psoriasis
Four-year data from open-label extension trials in moderate-to-severe plaque psoriasis showed durable skin clearance in patient treated with bimekizumab. Among Week 16 PASI 0 responders, Almost half (48.9%) of patients sustained complete skin clearance through 4 years.
"Achieving complete skin clearance is a key treatment target for all patients with plaque psoriasis, as it prevents the cumulative burden of disease and potentially progression to PsA," said Richard B. Warren, Professor of Dermatology, University of Manchester and Northern Care Alliance NHS Foundation Trust, in a UCB news release. "It is therefore highly relevant to observe complete skin clearance sustained over 4 years in nearly half of patients who received bimekizumab, demonstrating long-term control of inflammation and the potential to improve patient outcomes."
Additional findings included resolution of nail psoriasis in over 80% of patients and maintenance of psoriatic arthritis screening scores below the diagnostic threshold in 98.1% of high-risk individuals over three years. The safety profile remained favorable and consistent across the extended treatment period.
Sources: UCB press releases, September 17, 2025.